Introduction
============

COPD is characterized by airflow limitation and the presence of airway inflammation.[@b1-copd-12-1507] Many COPD patients suffer with exacerbations, defined as an acute deterioration in symptoms greater than the usual day-to-day variation[@b1-copd-12-1507] These events are often caused by bacterial infection.[@b2-copd-12-1507] COPD patients appear to have reduced ability to clear bacteria from the airways,[@b3-copd-12-1507] predisposing to bacterial colonization both in the stable state and at exacerbation. Bacterial infection increases the levels of airway inflammation.[@b2-copd-12-1507]

*Haemophilus influenzae* is one of the most commonly isolated bacterial pathogens from COPD patients.[@b2-copd-12-1507],[@b4-copd-12-1507] It can be capsulated or noncapsulated based on the presence or absence of a polysaccharide capsule. Noncapsulated *H. influenzae* (*NTHi*) is frequently isolated from COPD patients both in the stable state and during exacerbations.[@b2-copd-12-1507],[@b4-copd-12-1507] COPD exacerbations may be caused by either new or persisting *H. influenzae* strains,[@b5-copd-12-1507],[@b6-copd-12-1507] with antigenic variation[@b5-copd-12-1507],[@b7-copd-12-1507] allowing evasion of the host immune response.[@b5-copd-12-1507] Simultaneous colonization with multiple strains of *H. influenzae* both in the stable state and during exacerbations may also occur.[@b5-copd-12-1507],[@b8-copd-12-1507]

Antibiotics are often used to treat COPD exacerbations. They may also be administered in the stable state to clear infection from colonizing bacteria. Frequent antibiotic treatment predisposes to the development of antibiotic-resistant pathogens,[@b7-copd-12-1507] which can occur by mutation.[@b6-copd-12-1507] There are reports of antibiotic resistance trends in COPD patients,[@b6-copd-12-1507],[@b9-copd-12-1507],[@b10-copd-12-1507] with geographic variations in the types of bacteria in the lungs and antibiotic resistance patterns.

*H. influenzae* resistance to β-lactams is either enzyme (β-lactamase) or non-enzyme mediated. Non-enzyme-mediated resistance occurs through mutations in penicillin-binding protein 3 (PBP3), with *ftsI* gene mutations identified as a cause of decreased β-lactam-binding affinity. This is termed β-lactamase-negative ampicillin resistance (BLNAR).[@b11-copd-12-1507] Disk diffusion and gradient tests are routinely used to evaluate the antibiotic sensitivity. BLNAR identification by gradient tests using ampicillin minimum inhibitory concentration (MIC) breakpoints[@b12-copd-12-1507] is called phenotypic BLNAR. However, results using these arbitrary breakpoints can poorly be associated with genetic confirmation, called genetic BLNAR (gBLNAR). Nevertheless, it has been reported that 31.6% of *H. influenzae* isolates from adults with pneumonia were resistant to ampicillin using MIC criteria and that two-thirds of these were due to gBLNAR.[@b13-copd-12-1507] Furthermore, BLNAR is reported to be the most common cause of the reduced susceptibility of *H. influenzae* to ampicillin in some regions.[@b14-copd-12-1507] To our knowledge, the prevalence of BLNAR in COPD patients in the stable state has not been reported.

We have investigated the antibiotic resistance patterns of *H. influenzae* present in the sputum of a cohort of COPD patients in the stable state, focusing on ampicillin resistance. The prevalence of enzyme- and non-enzyme-mediated ampicillin resistance was determined, with confirmation of BLNAR by genetic analysis of *ftsI*. A subset of patients was followed up longitudinally to investigate the relationship between *H. influenzae* strain switching and antibiotic sensitivity.

Patients and methods
====================

Subjects
--------

Sixty-one COPD patients aged ≥40 years were recruited. All patients had a physician diagnosis of COPD, post-bronchodilator forced expiratory volume in 1 s (FEV~1~)/forced vital capacity (FVC) ratio \<0.7, ≥10-pack year smoking history, and no previous asthma diagnosis. All subjects provided written informed consent using a protocol approved by the Greater Manchester South Ethics Committees (10/H/1003/108).

Study design
------------

Demographic details, lung function, symptoms, health status, and previous exacerbation history were recorded at the base-line visit. Sputum samples were collected at this visit, and the patients were asked to return at 6, 12, 18, and 24 months for the collection of sputum samples in the stable state.

Sputum analysis
---------------

Spontaneous or induced sputum was processed for quantitative polymerase chain reaction (qPCR) detection of the common respiratory potentially pathogenic microorganisms *H. influenzae*, *Moraxella catarrhalis*, and *Streptococcus pneumoniae* in the baseline and 6-month samples. Briefly, selected sputum plugs were weighed and suspended in eight times volume of phosphate-buffered saline. Glass beads were added to this suspension, and it underwent homogenization by vortexing for 15 s, rocking for 15 min, and vortexing for an additional 15 s. Aliquots of 500 µL were stored at −80°C for subsequent qPCR processing.

Quantitative culture
--------------------

Sputum quantitative culture was performed according to standard practice.[@b15-copd-12-1507] Briefly, sputum was cultured onto suitable agar plates, that is, Columbia blood agar (a general growth media), Chocolate agar (for fastidious bacteria), MacConkey agar (for gram-negative bacteria), and Columbia Blood Agar Base (COBA) agar (*Streptococcus* selective supplement). The plates were incubated for 24--48 h at 37°C and 5% CO~2~ and identi-fied accordingly to standard practice using X and V tests.[@b15-copd-12-1507] All identified *H. influenzae* isolates were stored in frozen broth (brain heart infusion broth + 15% glycerol) at −80°C.

Antibiotic sensitivity testing
------------------------------

The antibiotic sensitivity testing by disk diffusion was performed and interpreted according to national guidelines[@b16-copd-12-1507] with antibiotics amoxicillin (2 µg), ampicillin (2 µg), amoxicillin-clavulanic acid (2:1 µg), cefaclor (30 µg), cefotaxime (5 µg), ceftazidime (30 µg), ceftriaxone (30 µg), imipenem (10 µg), azithromycin (15 µg), erythromycin (5 µg), clarithromycin (2 µg), moxifloxacin (5 µg), ciprofloxacin (1 µg), levofloxacin (1 µg), chloramphenicol (10 µg), trimethoprim-sulfamethoxazole (25 µg), and tetracycline (10 µg). Ampicillin results were interpreted as resistant if the zone diameter is ≤17 mm and interpreted as sensitive if the zone diameter is ≥18 mm.[@b16-copd-12-1507]

Enzyme-mediated β-lactamase detection
-------------------------------------

Enzyme-mediated resistance was detected with β-lactamase production test by chromogenic assay using nitrocefin as the substrate (Sigma-Aldrich, Poole, UK).

DNA extractions
---------------

From homogenized sputum samples, DNA was extracted using the MagNA Pure 96 DNA and Viral NA Small Volume Kit (Roche Diagnostics, Forenstrasse, Switzerland), as per the manufacturer's instructions. From pure bacterial isolates, DNA was extracted with chelex-100 using InstaGene Matrix (Bio-Rad, Hertfordshire, UK). The extracted DNAs were stored at 4°C for short term and at −80°C for long term.

qPCR analysis
-------------

A triplex quantitative real-time PCR was used for detection and quantification of three potentially pathogenic microorganisms; targeting the lipo-oligosaccharide glycosyltransferase-encoding gene (*lgtC*) of *H. influenzae*, the CopB outer membrane protein-encoding gene (*copB*) of *M. catarrhalis*, and the autolysin-encoding gene (*lytA*) of *S. pneumoniae.* The sequences of the primers and probe for the *lytA* were described elsewhere.[@b17-copd-12-1507] The presence of potential pathogenic microorganisms was defined as detection above the lower limit of detection for each pathogen corresponding to 2,000, 15,000, and 12,875 copies/mL, respectively, for *H. influenzae*, *M. catarrhalis*, and *S. pneumoniae*.

PCR and DNA sequencing
----------------------

All PCR primers were obtained from Eurofins Genomics, Germany. All end point PCR reactions and sample preparation for DNA sequencing were carried out in-house, and all sequencing work was outsourced to Eurofins Genomics.

Phenotypic BLNAR
----------------

The MICs were performed using E-strip (Oxoid-Thermo Scientific, Basingstoke, UK) gradient method. The measured MIC corresponds to 90% of inhibition of bacterial growth. For phenotypic classification of BLNAR, a MIC breakpoints of \>1 µg/mL was used.[@b12-copd-12-1507]

Genetic BLNAR
-------------

For genotypic resistance determination of BLNAR (gBLNAR), PCR amplifications and sequencing of the PBP3 locus of *ftsI* were carried out as described previously.[@b18-copd-12-1507] The DNA sequences were analyzed using Clustal Omega -- a multiple sequence alignment program for both DNA and proteins ([www.ebi.ac.uk/Tools/msa/clustalo/](http://www.ebi.ac.uk/Tools/msa/clustalo/)). The DNA sequences were translated to their corresponding peptide sequences using EMBOSS Transeq ([www.ebi.ac.uk/Tools/st/emboss_transeq/](http://www.ebi.ac.uk/Tools/st/emboss_transeq/)). The translated amino acid sequences were compared with the corresponding fragment of PBP3 from *H. influenzae* reference strain *RdKW20* for identifying specific amino acid substitutions and their positions. There are three classes of gBLNAR: class I has substitutions of arginine 517 for histidine (Arg517His), class II has substitutions of asparagine 526 for lysine (Asn526Lys) near the Lys--Thr--Gly (KTG) motif, and class III have the substitutions methionine for isoleucine (Met377Ile), serine for threonine (Ser385Thr), and leucine for phenylalanine (Leu389Phe) near the Ser--Ser--Asn (SSN) motif in addition to asparagine 526 for lysine (Asn526Lys).

Biotyping
---------

Biotyping was performed using three biochemical reactions: urease and indole production and ornithine decarboxylase reaction.[@b19-copd-12-1507] The eight biotypes of *H. influenzae* (I--VIII) can be identified based on the biochemical reactions.

Multilocus sequence typing (MLST)
---------------------------------

The MLST was carried out as described elsewhere.[@b20-copd-12-1507] Briefly, it included amplifying seven housekeeping genes (*adk*, *atpG*, *frdB*, *fucK*, *mdh*, *pgi*, and *recA*) and sequencing to determine the allele numbers of each gene for subsequently identifying the sequence type (ST). Allele numbers and ST were assigned using *H. influenzae* MLST website (<http://pubmlst.org/hinfluenzae/>). The database was analyzed using eBURST v3 to define groups from the available 1036 STs representing entire NTHi population in the database (accessed on July 15, 2016) for identifying related genotypes. The STs were included in a group if they shared alleles at a minimum of six of the seven loci, that is, single-locus variants (SLVs).

Results
=======

The baseline demography of the 61 subjects at the start of the study is shown in [Table 1](#t1-copd-12-1507){ref-type="table"}. The mean FEV~1~ predicted was 48.9%, and the mean St George's Respiratory Questionnaire was 54.7, suggesting a high burden of symptoms. Forty-two subjects produced sufficient sputum samples for qPCR analysis at the baseline visit; *H. influenzae* was present in 28 (67%) of these samples, either as the only pathogen or with other pathogens ([Table 1](#t1-copd-12-1507){ref-type="table"}). Of these 42 subjects, 37 also had a quantitative culture sample available at baseline. Comparison of the techniques showed that qPCR had increased sensitivity for detecting bacteria compared to culture ([Figure 1](#f1-copd-12-1507){ref-type="fig"}); bacteria were not detected in 73% of samples using culture compared to 35% using qPCR. Of the 61 patients, 2 were on long-term azithromycin: neither patient had *H. influenzae* present in sputum samples.

Follow-up for 2 years was completed in 45 subjects. There were 90 samples for quantitative culture, from which 24 *H. influenzae* isolates were obtained; 9 subjects provided one isolate and 6 subjects provided an isolate on more than one visit.

Disk diffusion antibiotic sensitivity
-------------------------------------

The antibiotic sensitivity testing results for all 24 *H. influenzae* isolates are presented in detail in [Table S1](#SD3-copd-12-1507){ref-type="supplementary-material"}. [Figure 2A](#f2-copd-12-1507){ref-type="fig"} shows the resistance in the first available *H. influenzae* isolate (n=15), and [Figure 2B](#f2-copd-12-1507){ref-type="fig"} shows the resistance in all the collected *H. influenzae* isolates (n=24). The highest percentage of resistance was observed in the penicillin antibiotic group (67% for ampicillin and 38% for amoxicillin-clavulanic acid) followed by the macrolides (46% for erythromycin, 21% for azithromycin, and 25% for clarithromycin). All 24 isolates were susceptible to quinolones.

Of the eight possible *H. influenzae* biotypes, the collected isolates belonged to biotypes I--IV, which is characteristic of respiratory isolates. The most common biotypes were III (46%) and II (42%). Biotype II showed a high prevalence of ampicillin resistance (80%) ([Figure 3](#f3-copd-12-1507){ref-type="fig"}).

From the six patients with *H. influenzae* isolates available on more than one visit, two subjects had ampicillin-resistant isolates at all visits, one subject had ampicillin-sensitive strains at all visits, and the remaining three subjects had *H. influenzae* isolates that changed between resistant and sensitive ([Table S1](#SD3-copd-12-1507){ref-type="supplementary-material"}).

β-Lactamase detection and BLNAR
-------------------------------

The 16 isolates resistant to ampicillin were selected for detecting β-lactamase enzyme production; 56% (9/16) were β-lactamase positive and 44% (7/16) were β-lactamase negative. The β-lactamase-negative isolates were further investigated for phenotypic and genotypic characterization of BLNAR ([Table S2](#SD4-copd-12-1507){ref-type="supplementary-material"}). None of the seven BLNAR isolates fulfilled the phenotypic BLNAR classification criteria of ampicillin MIC \>1 µg/mL. Only one of the seven β-lactamase-negative isolates was classified as gBLNAR due to a PBP3 mutation ([Table S3](#SD5-copd-12-1507){ref-type="supplementary-material"}). Three isolates had no amino acid substitutions in the PBP3 transpeptidase domain and three had mutations outside the KTG or SSN motif termed miscellaneous (M) mutations.[@b21-copd-12-1507]

Strain switching--MLST analysis
-------------------------------

MLST was carried out on 15 isolates from six subjects with a sample available on more than one visit ([Table 2](#t2-copd-12-1507){ref-type="table"}). These 15 isolates were assigned to 13 different STs: 11 were known STs (ie, STs already present in the database) and 2 were new STs (ST1608 and ST1562). The allelic profiles of each ST are presented in [Table S4](#SD6-copd-12-1507){ref-type="supplementary-material"}.

Two patients showed stable ST and biotype over 6 months. For the other four patients, ST changed at each visit, which was associated with either no biotype change or a biotype switch, with no predictable pattern observable. The previously identified genetically determined BLNAR isolate was identified as ST367, which is a known BLNAR strain.[@b22-copd-12-1507] There was no clear association between the occurrence of an exacerbation between visits and changes in either biotype or MLST.

For the two patients with no ST change, there was no change in antibiotic sensitivity by disk diffusion in one subject, whereas ampicillin and clarithromycin sensitivity changed in the other subject. For the remaining four patients with ST changes, there were changes in antibiotic sensitivity in three subjects, but no change in one subject despite ST switch.

The eBURST analysis using SLV revealed 10 groups ([Table 3](#t3-copd-12-1507){ref-type="table"}). Three STs were classified into eBURST group 2, which contains 39 possible NTHi isolates belonging to 37 STs deposited onto the MLST database. The predicted founder of this clonal group 2 is ST3, which was observed in one sample in this study.

All of the observed STs were related to other NTHi STs in the database with none existing as singletons. Five STs (ST3, ST11, ST57, ST349, and ST486) are predicted founders of their respective groups ([Figure S1](#SD1-copd-12-1507){ref-type="supplementary-material"}).

In the entire *H. influenzae* MLST database, there were 88 records from COPD and 24 records from the UK. There was only one ST present in our study that is also present in the MLST database, namely, ST57 ([Figure S2](#SD2-copd-12-1507){ref-type="supplementary-material"}).

Discussion
==========

Cross-sectional analysis of sputum samples obtained at the baseline visit in a cohort of stable COPD patients identified that approximately two-thirds of the subjects had *H. influenzae* present in the airways measured by qPCR. Disk diffusion, which is commonly used in clinical practice, demonstrated a relatively high rate of *H. influenzae* penicillin resistance (eg, 16 of 24 isolates for ampicillin), in contrast to quinolones, where all isolates were susceptible. β-Lactamase production was confirmed in 9/24 *H. influenzae* isolates, whereas gBLNAR was found in one isolate by *ftsI* sequencing. These results indicate the overidentification of ampicillin resistance by disk diffusion, and that the majority of confirmed resistance is due to enzyme production. Longitudinal follow-up showed that a high proportion of *H. influenzae* isolates demonstrated ST change, which was often associated with a change in antibiotic sensitivity.

Penicillin and macrolide antibiotics are often used as an empirical therapy for upper respiratory tract infections in COPD patients. Furthermore, some COPD patients are prescribed long-term macrolide treatment due to its antibacterial and anti-inflammatory properties. We show that many *H. influenzae* isolates are resistant to either one or both of these antibiotics. Long-term prescribing of macrolides can encourage the rapid emergence of antibiotic-resistant strains. In contrast, all *H. influenzae* isolates were susceptible to quinolones, suggesting that this class of drug can be used in preference to eradicate *H. influenzae* infection in COPD patients. A recent report from a cohort of COPD patients in the US has also demonstrated a high level of susceptibility of *H. influenzae* to quinolones.[@b10-copd-12-1507]

The confirmed ampicillin resistance identified here either by enzyme production or by *ftsI* mutation was 41.6% (10/24), which is higher than the UK national average of 21.4%.[@b23-copd-12-1507] This apparent high prevalence is likely to be due to our data received from COPD patients rather than a general population, with increased antibiotic use in COPD patients selectively allowing proliferation of resistant strains. The β-lactamase production was confirmed in 9 of 24 (37.5%) *H. influenzae* iso-lates. The UK has relatively higher *H. influenzae* β-lactamase prevalence compared with most other European countries.[@b24-copd-12-1507]

Six isolates classified as ampicillin resistant by disk diffusion did not produce β-lactamase and did not show evidence of meeting either phenotypic BLNAR definition criteria (ampicillin MIC \>1 µg/mL) or gBLNAR definition due to a PBP3 mutation. Such major errors in classification between methods have been previously reported where disk diffusion suggests the presence of a BLNAR mutation, but sequencing shows no mutations.[@b25-copd-12-1507] The optimum methods for documenting ampicillin resistance are through measuring β-lactamase production and genetic sequencing; of the 16 isolates classified as ampicillin resistant by disk diffusion, 10 were confirmed by one of these methods. This gives a true-positive and a false-positive rate for disk diffusion in this context of 62.5% and 37.5%, respectively. It should be noted that mechanisms other than PBP3 mutations or β-lactamase production were not investigated in our study such as mutations in the *acrR* gene.[@b26-copd-12-1507]

We used European Committee on Antimicrobial Suscep-tibility Testing MIC cutoff value of \>1 µg/mL (in contrast to Clinical and Laboratory Standards Institute cutoff values of \>2 µg/mL) to identify phenotypic BLNAR but found disagreement between this result and sequencing for the one gBLNAR isolate discovered. The clinical relevance of current breakpoints has been debated.[@b11-copd-12-1507],[@b26-copd-12-1507]--[@b28-copd-12-1507] The MIC of gBLNAR has been previously reported between 0.5 and 16 µg/mL,[@b11-copd-12-1507],[@b26-copd-12-1507],[@b27-copd-12-1507] and the reduced reliability of gradient tests for *H. influenzae* sensitivity to aminopenicillins has been documented.[@b29-copd-12-1507]

The low prevalence of *H. influenzae* gBLNAR in our population is consistent with the reported prevalence of 1.5% in the UK, whereas in European countries, the range is between 15% and 30%.[@b13-copd-12-1507],[@b30-copd-12-1507],[@b31-copd-12-1507] Our BLNAR isolate had a characteristic substitution pattern (D350N, M377I, A502V, N526K, V547I, and N569S) that has been previously reported.[@b22-copd-12-1507] This genotype confirmed *H. influenzae* isolate belonged to ST367; it has previously been reported that ST367 and ST14 have increased prevalence of PBP3 substitutions.[@b13-copd-12-1507],[@b22-copd-12-1507],[@b32-copd-12-1507] The dissemination of resistant clones of *H. influenzae* isolates from the upper respiratory tract has been demonstrated,[@b33-copd-12-1507] and it is possible that the gBLNAR ST367 that we observed could clonally disseminate to other individuals including COPD patients. In addition, continuous, unnecessary antibiotic prescription may cause a shift from low to high level penicillin binding protein resistance; such a shift has been noted in respiratory isolates of *H. influenzae*.[@b34-copd-12-1507] Miscellaneous PBP3 mutations were identified[@b21-copd-12-1507] outside the SSN and KTG motifs; their significance toward contributing to β-lactam resistance is unknown.

The appearance of different *H. influenzae* strains during longitudinal follow-up is known to occur in stable COPD patients.[@b4-copd-12-1507]--[@b6-copd-12-1507] A strain may be present, then absent, and then reappear.[@b4-copd-12-1507],[@b5-copd-12-1507],[@b8-copd-12-1507] This reappearance of the same strain could be due to host clearance and then reinfection or lack of methodological sensitivity in bacterial detection. In order to investigate whether the same or different strains appear over time, we have used the most sensitive method for detecting ST change, namely, MLST. Despite the relatively small number of patients in this particular analysis (n=6), we observed strain switching in four patients and the same strain was observed in two patients. Most strain switches were associated with at least one exacerbation between sample collections, which clearly could be key events causing changes in lung microbiome.

There were some changes in antibiotic sensitivity in one of the two patients with no ST change. Given the issues already discussed concerning overidentification of antibiotic resistance using disk diffusion, it is possible that method variability may cause an apparent change in sensitivity in the same strain. Most of the instances of strain change were associated with changes in antibiotic sensitivity. In clinical practice, empirical antibiotic treatment in COPD often follows the pattern of antibiotic sensitivity from historical experience, but our results highlight the frequent changes in antibiotic sensitivity that occur due to *H. influenzae* strain switching.

Biotypes II and III were the most prevalent in our *H. influenzae* isolates. Biotyping provides a limited amount of information regarding *H. influenzae* strain stability or change over time, and we show that ST change can cause either a change or no change in biotype.

Analysis using eBURST revealed a large number of singletons present with little clustering, signifying diversity present among NTHi. Comparison of our isolates to the database did not show that any particular group or groups of STs were present in COPD patients; this means that any ST can potentially be present in COPD patients. The heterogeneity in our *H. influenzae* population indicates that there are no *H. influenzae* strains with an increased predilection to colonize COPD lungs.

A limitation of our study is that the sample size for some analysis was relatively small. However, the detailed molecular description of BLNAR by PBP3 sequencing and of strain switching by MLST provides robust data, albeit in limited samples. In additional, we were not able to record the types of antibiotic used between sputum sampling, so we could not identify antibiotics that may have caused resistance.

Conclusion
==========

We show a significant prevalence of penicillin resistance in *H. influenzae* isolated from COPD patients, mainly due to β-lactamase production. We also demonstrate that *H. influenzae* present in the lungs of COPD patients show frequent ST change over time, which can change antibiotic resistance. These results highlight the changes in antibiotic sensitivity that occurs due to *H. influenzae* strain switching in COPD patients.

Supplementary materials
=======================

###### 

eBURST analysis for defining groups.

**Notes:** Analysis of NTHi isolates allelic profile to a list of all NTHi isolates profile in the database using eBURST. STs differing from another ST by only one of the seven loci are connected by lines and form a group. Pink spots represent the known 11 STs. Green spots represent the new STs found in our study. Blue spots represent the founding ST for each cluster. Yellow spots represent the subgroup founder for each cluster.

**Abbreviation:** ST, sequence type.

###### 

A comparison of the 13 STs from our study with COPD STs in the database.

**Notes:** The ST57 (pink) was present in the database of COPD STs, while, the remaining 12 STs (green) were not present in the database as STs from COPD. The blue spot represents the founding ST for each cluster. The yellow spot represents the subgroup founder.

###### 

Antibiotic sensitivity from the *H. influenzae* isolates in stable COPD patients

  Patient   Visit       Antibiotic sensitivity   Biotype                                                                                        
  --------- ----------- ------------------------ --------- ----- ----- ----- ----- ----- ----- ----- --- ----- ----- ----- ----- --- ----- ---- -----
  Pt 1      Baseline    AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
            6 months    AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
            12 months   AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
            24 months   AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
  Pt 2      18 months   AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   IV
            24 months   AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   IV
  Pt 3      6 months    AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
            12 months   AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
            18 months   AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
  Pt 4      Baseline    AML                      AMP       AMC   CEC   CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
            18 months   AML                      AMP       AMC   EC    CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
  Pt 5      12 months   AML                      AMP       AMC   EC    CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
            18 months   AML                      AMP       AMC   EC    CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
  Pt 6      6 months    AML                      AMP       AMC   EC    CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
            18 months   AML                      AMP       AMC   EC    CTX   CRO   CAZ   IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
  Pt 7      18 months   AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
  Pt 8      Baseline    AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
  Pt 9      6 months    AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
  Pt 10     24 months   AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
  Pt 11     6 months    AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III
  Pt 12     6 months    AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
  Pt 13     12 months   AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   II
  Pt 14     18 months   AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   I
  Pt 15     Baseline    AML                      AMP       AMC   EC    CTX   CRO   AZ    IPM   AZM   E   CLR   MXF   CIP   LEV   C   SXT   TE   III

**Notes:** Red color = resistance to antibiotic. Green color = sensitive to antibiotic. Gray color = patient reporting an exacerbation that had occurred since the previous visit. AML, amoxicillin (2 µg); AMP, ampicillin (2 µg); AMC, amoxi-clavulanic acid (3 µg 2:1 ratio); CEC, cefaclor (30 µg); CRO, ceftriaxone (30 µg); IMP, imipenem (10 µg); AZM, azithromycin (15 µg); E, erythromycin (5 µg); CLR, clarithromycin (2 µg); MXF, moxifloxacin (1 µg); CIP, ciprofloxacin (1 µg); LEV, levofloxacin (1 µg); C, chloramphenicol (10 µg); SXT, trimethoprim-sulfamethoxazole (25 µg); TE, tetracycline (10 µg).

**Abbreviations:** *H. influenzae*, *Haemophilus influenzae*; pt, patient.

###### 

Non-enzyme-mediated detection of resistance in ampicillin-resistant isolates that were negative for β-lactamase detection

  Patient   Visit      Non-enzyme mediated   Biotype    
  --------- ---------- --------------------- ---------- -----
  Pt 1      Baseline   \<0.015               No         III
            6 M        0.25                  No         III
            24 M       0.5                   No         II
  Pt 3      6 M        0.50                  No         III
            12 M       1.00                  Class II   II
  Pt 6      18 M       1.00                  No         II
  Pt 10     24 M       0.25                  No         II

**Abbreviations:** BLNAR, β-lactamase-negative ampicillin resistance; MIC, minimum inhibitory concentration; gBLNAR, genetic BLNAR; pt, patient; M, months.

###### 

Amino acid substitutions in the transpeptidase domain of PBP3 (amino acids from 338 to 573) identified in seven *H. influenzae* isolates

  PBP3 amino acid substitutions                                                                            
  ------------------------------- ---------- ------------ ----- ----- -- -- -- ----- ----- --------- ----- -----
  Pt 1                            Baseline   Not gBLNAR                                                    
                                  6 M        Not gBLNAR                                              Ile   
                                  24 M       Not gBLNAR   Asn                  Ser                   Ile   Ser
  Pt 3                            6 M        Not gBLNAR                                                    
                                  12 M       Class II     Asn   Ile                  Val   **Lys**   Ile   Ser
  Pt 6                            18 M       Not gBLNAR   Asn                  Ser                   Ile   Ser
  Pt 10                           24 M       Not gBLNAR                                                    

**Notes:**

The amino acid sequence of PBP3 from *H. influenzae* reference strain RdKW20 used for identifying specific amino acid substitutions and their positions.

Substitutions of methionine for isoleucine (Met377Ile), serine for threonine (Ser385Thr), and leucine for phenylalanine (Leu389Phe) near the Ser--Ser--Asn (SSN) motif in addition to asparagine 526 for lysine (Asn526Lys) equals class III.

Substitution of arginine 517 for histidine (Arg517His) equals class I gBLNAR.

Substitutions of asparagine 526 for lysine (Asn526Lys) near the Lys--Thr--Gly (KTG) motif equals class II gBLNAR.

**Abbreviations:** PBP3, penicillin-binding protein 3; *H. influenzae*, *Haemophilus influenzae*; gBLNAR, genetic β-lactamase-negative ampicillin resistance; pt, patient; M, months.

###### 

Allelic profiles of *H. influenzae* isolates in this study

  Patient   Visit      ST                                                   Allelic profiles                             
  --------- ---------- ---------------------------------------------------- ------------------ ---- ----- ---- ---- ---- ----
  Pt 1      Baseline   11                                                   1                  8    1     14   9    14   13
            6 M        1,608[a](#tfn16-copd-12-1507){ref-type="table-fn"}   16                 8    160   48   10   1    3
            12 M       436                                                  40                 1    1     10   15   1    5
            24 M       263                                                  28                 14   1     1    16   55   1
  Pt 2      18 M       986                                                  35                 1    22    36   7    58   29
            24 M       986                                                  35                 1    22    36   7    58   29
  Pt 3      6 M        46                                                   1                  25   1     14   15   1    5
            12 M       367                                                  1                  1    1     1    67   1    5
            18 M       1,562[a](#tfn16-copd-12-1507){ref-type="table-fn"}   1                  7    1     1    67   1    5
  Pt 4      Baseline   57                                                   14                 7    13    7    17   13   17
            18 M       3                                                    1                  1    1     1    1    1    5
  Pt 5      12 M       388                                                  60                 51   16    48   15   1    31
            18 M       388                                                  60                 51   16    48   15   1    31
  Pt 6      6 M        411                                                  14                 7    13    30   1    21   1
            18 M       349                                                  28                 14   13    1    62   13   1

**Note:**

A new ST identified in this study.

**Abbreviations:** *H. influenzae*, *Haemophilus influenzae*; ST, sequence type; pt, patient; M, months.
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![Detection of bacteria by culture and qPCR (n=37 paired samples).\
**Notes:** qPCR: negative is defined if the count was below the limit of detection for each pathogen. Culture: negative is defined as no bacteria detected. No lower limit of detection was applied.\
**Abbreviations:** qPCR, quantitative polymerase chain reaction; HI, *Haemophilus influenzae*; SP, *Streptococcus pneumoniae*; MC, *Moraxella catarrhalis*.](copd-12-1507Fig1){#f1-copd-12-1507}

![Antibiotic sensitivity of *H. influenzae* isolates from (**A**) the first stable visit (n=15); and (**B**) all *H. influenzae* isolates (n=24).\
**Abbreviation:** *H. influenzae*, *Haemophilus influenzae*.](copd-12-1507Fig2){#f2-copd-12-1507}

![Biotype distribution among ampicillin-resistant and ampicillin-sensitive *H. influenzae* isolates (n=24).\
**Abbreviation:** *H. influenzae*, *Haemophilus influenzae*.](copd-12-1507Fig3){#f3-copd-12-1507}

###### 

Baseline demographics and qPCR detection of bacterial pathogens

  Demographic                                                         n=61
  ------------------------------------------------------------------- --------------------
  Age (years)                                                         64.5 (5.4)
  Gender, male (%)                                                    69
  Current smoker (%)                                                  38
  Pack years                                                          45.0 (11.1--172.0)
  BMI (kg/m^2^)                                                       26.7 (5.2)
  Exacerbations (12 months prior)                                     2 (0--6)
  Frequent exacerbations (≥2 in 12 months prior) (%)                  56
  Chronic bronchitis (%)                                              69
  Inhaled steroid use (%)                                             84
  LAMA only (%)                                                       8
  LABA + LAMA use (%)                                                 3
  ICS + LABA use (%)                                                  15
  LABA + LAMA + ICS (%)                                               69
  CAT                                                                 23 (2--37)
  mMRC                                                                2 (0--4)
  SGRQ total                                                          50.6 (22.6)
  Post-bronchodilator FEV~1~ (L)                                      1.3 (0.5)
  Post-bronchodilator FEV~1~ (%)                                      48.9 (16.2)
  Post-bronchodilator FEV~1~, \<50 (%)                                57
  Post-bronchodilator FEV~1~/FVC (%)                                  41.5 (10.1)
                                                                      
  **qPCR detection of bacteria**                                      
                                                                      
  **42 qPCR samples**                                                 **n (%)**
                                                                      
  No pathogens detected[a](#tfn2-copd-12-1507){ref-type="table-fn"}   14 (33)
  *H. influenzae*                                                     15 (36)
  *H. influenzae* + *M. catarrhalis*                                  7 (17)
  *H. influenzae* + *M. catarrhalis* + *S. pneumoniae*                4 (10)
  *H. influenzae* + *S. pneumonia*                                    2 (5)

**Notes:** Summaries are presented as percentage, mean (SD), or median (range) as appropriate.

No pathogens detected = if count was below the limit of detection for each pathogen.

**Abbreviations:** qPCR, quantitative polymerase chain reaction; BMI, body mass index; LAMA, long-acting muscarinic antagonist; LABA, long-acting beta agonist; ICS, inhaled corticosteroid; FEV~1~, forced expired volume in 1 s; FVC, forced vital capacity; *H*. *influenzae*, *Haemophilus influenzae*; *M*. *catarrhalis*, *Moraxella catarrhalis*; *S*. *pneumoniae*, *Streptococcus pneumoniae*; CAT, COPD Assessment Test; mMRC, Modified Medical Research Council.

###### 

MLST in multiple stable isolates available within a patient

  Patient   Visit      Biotype   MLST
  --------- ---------- --------- ---------------------------------------------------
  Pt 1      Baseline   III       11
            6 M        III       1,608[a](#tfn5-copd-12-1507){ref-type="table-fn"}
            12 M       II        436
            24 M       II        263
  Pt 2      18 M       IV        986
            24 M       IV        986
  Pt 3      6 M        III       46
            12 M       II        367
            18 M       II        1,562[a](#tfn5-copd-12-1507){ref-type="table-fn"}
  Pt 4      Baseline   II        57
            18 M       II        3
  Pt 5      12 M       III       388
            18 M       III       388
  Pt 6      6 M        III       411
            18 M       II        349

**Notes:** Gray shading represents patient reporting an exacerbation had occurred since the previous visit.

Assigned new ST in this study.

**Abbreviations:** MLST, multilocus sequence typing; pt, patient; M, months; ST, sequence type.

###### 

eBURST group numbers and the number of isolates in each group

  eBURST group number   No of STs in each group
  --------------------- -------------------------
  1                     2
  2                     3
  5                     1
  9                     1
  11                    1
  15                    1
  36                    1
  54                    1
  94                    1
  97                    1

**Abbreviation:** STs, sequence types.
